PTC Therapeutics

Email Page

Print Page

Glossary

Site Map

Get Flash

Ataluren (PTC124™) is a novel, orally administered, small-molecule, investigational new drug for the treatment of genetic disorders resulting from nonsense mutations. Read more »

> Ataluren Summary

> Frequently Asked Questions

> Contact us to submit questions or join our update list

PTC is a committed group of people that has a passion for science and a desire to succeed. Learn more »

Click below for more information on current clinical trials.

> PTC299 for Metastatic Breast Cancer

>PTC299 for Advanced Solid Tumors

6/15/2009 - PTC Therapeutics Receives $2.6 Million in Government Grants Read more »

More PTC news »

Find out what meetings PTC Therapeutics will be attending to learn more about our company and our technology.